Assessment of laboratory performance for the detection of drug resistance mutations in hepatitis B virus through international proficiency testing

s / Journal of Clinical Virology 70 (2015) S1–S126 S107 of both techniques, was 0.931. The Bland-Altman mean difference estimated between the two methods was 0.301 Log IU/mL. Precision was measured as the Coefficient of Variation (CV) intra and inter-assay by processing duplicated samples corresponding to a range of 5 levels of values during 20 consecutive days: Mean CV was 1.92%, 3.12% and 7.75% for HIV-1 protocol 1mL and 175 l, and HCV respectively. Specificity forVeris/DxNon180and203negative samples was 99% and 100% for HIV-1 and HCV assays respectively. Conclusion: The Veris/DxN System for HIV-1 and HCV VL monitoring is a completely automated system for rapid and random access processing of plasma and serum samples. Overall performance and easy-to-use design facilitated introduction of the technology in the laboratory. Both HIV-1 1mL and 175 l protocols, andHCVtechniqueswereextremely sensitiveandspecific, and exhibited a high linearity and repeatability. The Veris/DxN System for HIV-1 and HCV Viral Load is a helpful new solution for patient management by molecular biology monitoring. http://dx.doi.org/10.1016/j.jcv.2015.07.247